Pharmac’s delay in getting drugs to market ‘not acceptable’ – Medicines NZ

Substantial delays in getting drugs to market in New Zealand compared with Australia is ‘not acceptable’ says Kevin Sheehy – General Manager of Medicines New Zealand.

The delays, which “are not liked to the regulator”, were evidence of the deficiencies1Z1-868 within Pharmac. In its current state, a lack of transparency and the absence of a consistent decision making process was hurting Pharmac,” Sheehy told the TPP Stakeholders Day in Auckland.

Sheehy called on TPP negotiators this week to consider patents and protections for the pharmaceutical industry.

“Data protection for biologicals is particularly important because of the less robust
70-298 protection offered during the 20 year patent term.”

The medical industry was in danger of continuing to advanced in the absence of f “incentivize bringing new and improved treatments to market.”